ROXRO Pharma

About ROXRO
- Overview
  - Milestones
- Management
- Board of Directors
- Scientific Advisors
- Investors
Product Candidates
- Pipeline
  - 888 / Acute Pain
  - 828 / Migraine
- Nasal Delivery of Pain Drugs
Business Development
News & Media
- Press Releases
- Publications
- Upcoming Events, Presentations
Contact Us
- Directions

You need to upgrade your Flash Player

A PHARMACEUTICAL COMPANY
focused on the treatment of pain

ROXRO PHARMA, Inc. is a late-stage specialty pharmaceutical company developing hospital strength acute pain products for convenient use by patients in the home setting. The company is led by a seasoned management team that has successfully discovered, developed and commercialized several pain and cardiovascular medicines that are widely prescribed today.

February 06, 2009

ROXRO Announces FDA Accepts for Review NDA for Sprix (formerly ROX-888). for the Management of Acute Moderate to Severe Pain

September 06, 2008

ROXRO PHARMA Presents Migraine Proof-of-Concept Data at the European Headache and Migraine Trust International Congress 2008

May 05, 2008

ROXRO PHARMA’s Phase 3 Intranasal Analgesic Data Receives Excellence Award

ROXRO is developing two products for the treatment of acute pain:

Sprix The Efficacy of
Hospital-Strength Ketorolac
in a Convenient Form

ROX-828 Rapid-Onset Non-Opioid, Non-Triptan Migraine Treatment